This report will be an essential resource for companies conducting preclinical development programs interested in:

• Moving candidates into clinical trials
• Adding informational value to candidates
• Accessing China's market
• Maximizing the probability of a successful candidate portfolio

Included in the report:

• China's regulations comparison with the US
• Main players
• Cost analysis
• Trends, drives, and competition issues
• Issues regarding outsourcing to China
• Service providers listed by background

Who benefits from this report?

• Drug discovery companies
• Entities involved in early stages of drug R&D with limited funds
• Entities wishing to choose high-potential candidates for development
• Pharmaceutical companies interested in filing for China's regulatory approval
• Preclinical service companies
• Investors
• Laboratories of institutes and universities
• Others who require information concerning outsourcing new drug development to China

Primary research sources:

• Preclinical laboratory staff
• Laboratory animal suppliers
• Pharmaceutical companies
• Drug R&D industry
• Leaders
• Managers
• Scientists
• Associations and government offices